Discontinued — last reported Q4 '17
Blackstone Intangibles (Net) decreased by 4.6% to $140.46M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 19.4%, from $174.27M to $140.46M. Over 4 years (FY 2020 to FY 2024), Intangibles (Net) shows a downward trend with a -17.0% CAGR.
High levels reflect significant investment in growth through acquisitions; changes indicate the impact of amortization or impairment charges.
This includes the value of acquired intellectual property, such as patents, trademarks, and drug licenses, net of accumu...
Very high in the pharmaceutical industry due to the reliance on patent-protected drug portfolios.
intangible_assets_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $321.78M | $303.08M | $284.38M | $265.69M | $246.99M | $232.10M | $217.29M | $230.30M | $219.22M | $210.21M | $201.21M | $192.23M | $183.25M | $174.27M | $165.24M | $156.27M | $147.29M | $140.46M |
| QoQ Change | — | -5.8% | -6.2% | -6.6% | -7.0% | -6.0% | -6.4% | +6.0% | -4.8% | -4.1% | -4.3% | -4.5% | -4.7% | -4.9% | -5.2% | -5.4% | -5.7% | -4.6% |
| YoY Change | — | — | — | — | -23.2% | -23.4% | -23.6% | -13.3% | -11.2% | -9.4% | -7.4% | -16.5% | -16.4% | -17.1% | -17.9% | -18.7% | -19.6% | -19.4% |